166 related articles for article (PubMed ID: 36878410)
21. Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients.
Van Matre ET; Teitelbaum I; Kiser TH
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122898
[TBL] [Abstract][Full Text] [Related]
22. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.
Dunne MW; Puttagunta S; Giordano P; Krievins D; Zelasky M; Baldassarre J
Clin Infect Dis; 2016 Mar; 62(5):545-51. PubMed ID: 26611777
[TBL] [Abstract][Full Text] [Related]
23. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.
Thomas G; Henao-Martínez AF; Franco-Paredes C; Chastain DB
Int J Antimicrob Agents; 2020 Sep; 56(3):106069. PubMed ID: 32603683
[TBL] [Abstract][Full Text] [Related]
24. In vitro time-kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times.
Di Pilato V; Ceccherini F; Sennati S; D'Agostino F; Arena F; D'Atanasio N; Di Giorgio FP; Tongiani S; Pallecchi L; Rossolini GM
Diagn Microbiol Infect Dis; 2020 Feb; 96(2):114901. PubMed ID: 31761480
[TBL] [Abstract][Full Text] [Related]
25. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
[TBL] [Abstract][Full Text] [Related]
26. Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort study.
Buzón Martín L; Mora Fernández M; Perales Ruiz JM; Ortega Lafont M; Álvarez Paredes L; Morán Rodríguez MA; Fernández Regueras M; Machín Morón MA; Mejías Lobón G
Rev Esp Quimioter; 2019 Dec; 32(6):532-538. PubMed ID: 31642637
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model.
Jabés D; Candiani G; Romanó G; Brunati C; Riva S; Cavaleri M
Antimicrob Agents Chemother; 2004 Apr; 48(4):1118-23. PubMed ID: 15047510
[TBL] [Abstract][Full Text] [Related]
28. Model-based Evaluation of the Clinical and Microbiological Efficacy of Vancomycin: A Prospective Study of Chinese Adult In-house Patients.
Shen K; Yang M; Fan Y; Liang X; Chen Y; Wu J; Yu J; Zhang H; Wang R; Zhang F; Hang J; Wen X; Li H; Shen L; Zhang Z; Wu S; Shen B; Huang W; Chang C; Shen Y; Ren H; Yuan Q; Song X; Luo X; Zhang H; Yang W; Yang J; Zhang J
Clin Infect Dis; 2018 Nov; 67(suppl_2):S256-S262. PubMed ID: 30423042
[TBL] [Abstract][Full Text] [Related]
29. Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus.
Werth BJ; Ashford NK; Penewit K; Waalkes A; Holmes EA; Ross DH; Shen T; Hines KM; Salipante SJ; Xu L
Clin Microbiol Infect; 2021 Jun; 27(6):910.e1-910.e8. PubMed ID: 32866650
[TBL] [Abstract][Full Text] [Related]
30. In vitro additive effects of dalbavancin and rifampicin against biofilm of Staphylococcus aureus.
Jacob B; Makarewicz O; Hartung A; Brodt S; Roehner E; Matziolis G
Sci Rep; 2021 Dec; 11(1):23425. PubMed ID: 34873186
[TBL] [Abstract][Full Text] [Related]
31. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen.
Werth BJ; Jain R; Hahn A; Cummings L; Weaver T; Waalkes A; Sengupta D; Salipante SJ; Rakita RM; Butler-Wu SM
Clin Microbiol Infect; 2018 Apr; 24(4):429.e1-429.e5. PubMed ID: 28782651
[TBL] [Abstract][Full Text] [Related]
32. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
Kebriaei R; Rice SA; Stamper KC; Rybak MJ
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013).
Huband MD; Castanheira M; Farrell DJ; Flamm RK; Jones RN; Sader HS; Mendes RE
Int J Antimicrob Agents; 2016 Jun; 47(6):495-9. PubMed ID: 27211209
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis.
Barnea Y; Lerner A; Aizic A; Navon-Venezia S; Rachi E; Dunne MW; Puttagunta S; Carmeli Y
J Antimicrob Chemother; 2016 Feb; 71(2):460-3. PubMed ID: 26518048
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: A case report.
Hakim A; Braun H; Thornton D; Strymish J
Int J Infect Dis; 2020 Feb; 91():202-205. PubMed ID: 31841726
[TBL] [Abstract][Full Text] [Related]
36. Dalbavancin treatment for spondylodiscitis: multi-center clinical experience and literature review.
Ramadan MS; Gallo R; Lugarà M; Gambardella M; Oliva G; Bertolino L; Andini R; Coppola N; Zampino R; Durante-Mangoni E
J Chemother; 2022 Oct; 34(6):360-366. PubMed ID: 34923922
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic potential of dalbavancin in a rat model of methicillin-resistant Staphylococcus aureus (MRSA)-osteomyelitis.
Silva V; Miranda C; Antão HS; Guimarães J; Prada J; Pires I; Maltez L; Pereira JE; Capelo JL; Igrejas G; Poeta P
Int J Antimicrob Agents; 2020 Jul; 56(1):106021. PubMed ID: 32439480
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic interaction between rifampicin and clindamycin in staphylococcal osteoarticular infections.
Goulenok T; Seurat J; Selle A; Jullien V; Leflon-Guibout V; Grall N; Lescure FX; Lepeule R; Bertrand J; Fantin B; Burdet C; Lefort A
Int J Antimicrob Agents; 2023 Aug; 62(2):106885. PubMed ID: 37302771
[TBL] [Abstract][Full Text] [Related]
39. Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections.
Morata L; Cobo J; Fernández-Sampedro M; Guisado Vasco P; Ruano E; Lora-Tamayo J; Sánchez Somolinos M; González Ruano P; Rico Nieto A; Arnaiz A; Estébanez Muñoz M; Jiménez-Mejías ME; Lozano Serrano AB; Múñez E; Rodriguez-Pardo D; Argelich R; Arroyo A; Barbero JM; Cuadra F; Del Arco A; Del Toro MD; Guio L; Jimenez-Beatty D; Lois N; Martin O; Martínez Alvarez RM; Martinez-Marcos FJ; Porras L; Ramírez M; Vergas García J; Soriano A
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858217
[TBL] [Abstract][Full Text] [Related]
40. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
Steele JM; Seabury RW; Hale CM; Mogle BT
J Clin Pharm Ther; 2018 Feb; 43(1):101-103. PubMed ID: 28628223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
